Johnson & Johnson makes $15 billion bet on mental-health drugs
Johnson & Johnson said Monday it expects to accelerate sales growth beyond Wall Street expectations in the field of ...
MarketBeat on MSN6d
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...
Johnson & Johnson Acquires Intra-Cellular in $14.6 Billion Deal
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
The Motley Fool1d
Johnson & Johnson (NYSE: JNJ)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...
Johnson & Johnson To Buy Intra-Cellular Therapies For $132.00/shr In $14.6 Bln All-cash Deal
Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement ...
Enid News & Eagle10d
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B
Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...